LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that it has regained compliance with Nasdaq ...
In related news, GRI Bio has conditionally regained compliance with Nasdaq’s equity listing rule, meeting the requirement of maintaining a minimum of $2.5 million in stockholders’ equity. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results